MAPT and familial Alzheimer disease: COs harboring the E200K mutation were previously used as negative controls for amyloid and Tau pathology in a study that demonstrated organoids from donors with Down Syndrome and familial Alzheimer’s disease spontaneously develop the pathological features of these disorders [8].